Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 10Carcinoma, Hepatocellular 5Colonic Neoplasms 4Rectal Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Adenocarcinoma 2Thrombocytosis 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Physician Education 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Noonan Syndrome 6 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Pancreatic Adenocarcinoma 1Melanoma 1MSI-H Colorectal Cancer 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1

Interventions

Sorafenib 12Radiosurgery 5Gemcitabine 5Capecitabine 5Bevacizumab 5Radiotherapy 4Fluorouracil 4Doxorubicin 4Sunitinib 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3seocalcitol 2regorafenib 2phosphomannopentaose sulfate 2atezolizumab 2Thiotepa 2Radiofrequency Ablation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Dexamethasone 2Cisplatin 2Chemoembolization, Therapeutic 2Carboplatin 2Busulfan 2Brachytherapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Liver Neoplasms × regorafenib × Clear all
NCT04476329 2021-12-30

ReDos HCC

SC Liver Research Consortium, LLC

Phase 2 Terminated
7 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03644511 2020-08-21

SORAGO-HCC

Bayer

Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡